5 results
To explore saftey and acceptability of three doses of an etonogestrel-releasing medicated intrauterine system (ENG-MIUS) as compared to Multiload-cu 375®.
Primary ObjectiveTo evaluate the clinical efficacy of apremilast (30 mg twice daily [BID] and 40 mg BID), compared with placebo, in subjects with active UC.Secondary Objective To evaluate the safety and tolerability of apremilast (30 mg BID and 40…
Primary Objective- To evaluate the clinical efficacy and safety of oral apremilast (APR) 30 mg twice a day (BID) compared with placebo, in subjects with moderate to severe plaque psoriasis at Week 16.Secondary Objectives- To evaluate the clinical…
• Allow patients to continue or start AP01 therapy for the treatment of ILD and IPF prior to regulatory approval or until the study is terminated• To evaluate safety outcomes of patients on AP01 therapy
The primary objective is to evaluate safety and tolerability of treatment with AP01.This study will also evaluate the effect of AP01 on various efficacy measures as follows:* To evaluate the safety and tolerability of treatment with AP01 when given…